Prosight Management’s Global Blood Therapeutics GBT Stock Holding History
Bought
Maintained
Sold
Other funds holding GBT
BBA
Prosight Management's GBT Position: Q3 2022 in Review
Prosight Management sold out of Global Blood Therapeutics (GBT) in Q3 2022, closing a stake of 101,847 shares — an estimated $3.25M sold.
Prosight Management first reported a position in GBT in Q2 2022 and held it in 1 quarter. The position peaked at $3.25M in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.
- Prosight Management reported no remaining Global Blood Therapeutics position as of Q3 2022 after selling out during the quarter.
- Prosight Management sold 101,847 Global Blood Therapeutics shares in Q3 2022, an estimated $3.25M.
- Prosight Management first reported a position in Global Blood Therapeutics in Q2 2022 and held it in 1 quarter.
- Prosight Management's Global Blood Therapeutics position peaked at $3.25M in Q2 2022.
- 247 funds tracked by Wall St. Rank held Global Blood Therapeutics as of Q3 2022.
Based on Prosight Management's 13F filing for Q3 2022, filed 14 Nov 2022.